We believe continued strong oncology sales and operational execution will sustain the premium multiple versus the peer group.

We remain cautious until we see significant evidence of accelerating sales, operational and commercial execution, and improved long-term visibility on sales and earnings growth.

Execution was the problem. We had a good game plan. We made adjustments. We just didn't execute. We had way too many mental errors and they turned into critical errors.

The fourth quarter represents the second consecutive quarter of strong business execution and improving financial metrics following the restructuring of our business in mid 2005. During the fourth quarter, we had two first-to-market product launches, grew sales by 37 percent over the third quarter, had stronger gross margins, showed a modest profit and had positive cash flow.

It looked to be a very strong quarter. I'm surprised by how strong the HIV franchise was.

The stock has gotten a lot cheaper.